Rigel Pharmaceuticals, Incorporated

Prosetta Antiviral, Inc.

Andy Atuegbu

Rajinder Paul Singh

Somasekhar Bhamidipati

Jeffrey Clough

Sambaiah Thota

Clarence R Hurt

Hui Li

Anatoliy Kitaygorodskyy

Vishwanath R Lingappa

Beverly Freeman

Ankush Argade

Jiaxin Yu

Ihab S Darwish

Pingyu Ding

Darren J McMurtrie

Carlos A Valdez

Hui Hong

Marina Gelman

John Yudhistir Ramphal

Vadim Markovtsov

Vanessa Taylor

David Carroll

Dennis Solas

Robin Cooper

Vadim Markovtosov

Anatoliy Kitaygorodorskyy

Sambiah Thota

John Ramphal

Darren Mcmurtrie

Anatoliy Kityagorodskyy

This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds

This invention is directed to methods of treating diseases or conditions associated with JAK2 activity in a mammal comprising the administration of a compound of formula (I): where n, m, Y, R, R, R, Rand Rare disclosed herein, or a pharmaceutically acceptable salt.

Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

Anti-HIV compounds

Disclosed embodiments provide pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.

Pyrimidinediamine kinase inhibitors

Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.

Antiviral compounds

Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and respiratory viruses including the common cold.

Novel compounds, methods, and compositions for treating various viral infections are described. In some embodiments the novel compounds of the invention are 3-oxo-phenothiazine derivatives; more specific embodiments include 3-oxo-phenothiazine derivatives having substituents at the 1-, 7-, and 9-positions of the phenothiazine parent ring. In other embodiments, the invention provides compositions and methods for treating viral infections, especially HIV.

This invention is directed to compounds of formula (I): where n, m, Y, R, R, R, Rand Rare disclosed herein, as isolated stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

This invention is directed to compounds of formula (I): where n, m, Y, R, R, R, Rand Rare disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.

Growing community of inventors

Dublin, CA, United States of America

Andy Atuegbu